We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
Turnover
15.59%
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+2.9%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.56B
AUM Growth
-$71.2M
(-2.7%)
Cap. Flow
-$99.6M
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
27
Reduced
32
Closed
20
Avg Time Held
4.2
years
Top 10 Avg Time Held
3.2
years
Top 20 Avg Time Held
4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$20M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$14.2M |
| 3 |
Amgen
AMGN
|
+$14.1M |
| 4 |
Insulet
PODD
|
+$13.3M |
| 5 |
Baxter International
BAX
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$31.7M |
| 2 |
Cigna
CI
|
+$22.5M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$22.3M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$13.8M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$13.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.28% |
| 2 | Real Estate | 2.09% |
| 3 | Miscellaneous | 1.37% |
| 4 | Industrials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
176
DELISTED
Merus
MRUS
| – | – |
-69,025
| Closed | -$1.27M | – |
|
177
Option Care Health
OPCH
$4.66B
| – | – |
-64,975
| Closed | -$2.06M | – |
|
178
Ultragenyx Pharmaceutical
RARE
$1.47B
| – | – |
-67,065
| Closed | -$2.69M | – |
|
179
Syndax Pharmaceuticals
SNDX
$1.21B
| – | – |
-117,717
| Closed | -$2.49M | – |
|
180
Travere Therapeutics
TVTX
$5.02B
| – | – |
-418,520
| Closed | -$9.41M | – |
|
181
Zai Lab
ZLAB
$2.53B
| – | – |
-34,640
| Closed | -$1.15M | – |
|
182
DELISTED
CATALENT, INC.
CTLT
| – | – |
-49,406
| Closed | -$3.25M | – |
|
|
VECT
183
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| – | – |
-682,834
| Closed | -$5.87M | – |
|
|
RXDX
184
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-50,538
| Closed | -$5.42M | – |
|
|
CSII
185
DELISTED
Cardiovascular Systems, Inc.
CSII
| – | – |
-174,859
| Closed | -$3.47M | – |
|
Similar funds
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Tekla Capital Management held 186 positions worth $2.56B, down 2.7% from $2.63B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Tekla Capital Management withdrew a net $99.6M in Q2 2023, closing 20 positions and reducing 32 holdings. Its most notable exit was Travere Therapeutics, an estimated $9.41M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Miscellaneous.
Against the trend, Tekla Capital Management opened a new position in Insulet worth $12.6M.
- Tekla Capital Management's largest Q2 2023 buy was Insulet: 43,847 shares worth $12.6M.
- Tekla Capital Management added most to Merck in Q2 2023, an estimated $20M increase.
- Tekla Capital Management's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $31.7M.
- Tekla Capital Management fully exited Travere Therapeutics in Q2 2023, selling an estimated $9.41M.
- Tekla Capital Management's ten largest holdings make up 40% of its $2.56B portfolio in Q2 2023.
- Tekla Capital Management opened 9 new positions and closed 20 in Q2 2023.
- Tekla Capital Management's portfolio value fell 2.7% quarter-over-quarter to $2.56B.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.